MGC026 Hits Phase 1 Goal in Head & Neck Cancer, Advances to Stage 2
MGNX has more than doubled off its 52-week low of $1.29.
Summary
MacroGenics' antibody-drug conjugate MGC026 met its pre-specified response threshold in the SCCHN cohort of a Phase 1 study, triggering advancement to Stage 2 enrollment. No serious safety signals were reported. This follows a recent 8-K disclosing the same milestone, but the news adds public confirmation and detail. The company's cash runway extends through 2028, reducing near-term dilution risk. The next catalyst will be initial efficacy data from Stage 2, though no timeline was provided.
At the time of this announcement, MGNX was trading at $4.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $254.9M. The 52-week trading range was $1.29 to $5.08. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.